"It is difficult to tell
the impact of this new drug launch on the treatment of epilepsy. However,
Xcopri trials demonstrated high efficacy in partial onset seizures and
refractory epilepsy, lending it a strong clinical profile. One could reasonably
suspect a high impact on the epilepsy treatment paradigm."
— Mesfin Tegenu, R.Ph., president of PerformRx, talked with
AIS's RADAR on Drug Benefits
about how the launch of Xcopri (cenobamate tablets) in May for the treatment of
partial-onset seizures in adults could affect the treatment of epilepsy.
Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment